A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
iOnctura
Ipsen
Ipsen
Ascentage Pharma Group Inc.
Eli Lilly and Company
Incyte Corporation
Curis, Inc.
Shenzhen BinDeBio Ltd.
Mayo Clinic
Novartis
Stanford University
Novartis
Valerio Therapeutics
University of Chicago